Equities

Transmedics Group Inc

Transmedics Group Inc

Actions
  • Price (EUR)117.45
  • Today's Change-0.05 / -0.04%
  • Shares traded0.00
  • 1 Year change+83.52%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

  • Revenue in USD (TTM)296.92m
  • Net income in USD-10.20m
  • Incorporated2018
  • Employees584.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TMDX:NMQ since
announced
Transaction
value
Summit Aviation IncDeal completed01 Aug 202301 Aug 2023Deal completed38.19%--
Data delayed at least 15 minutes, as of May 09 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.